Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Promacta, Revolade
Promacta (eltrombopag) is an orally administered, small molecule thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It is also used for severe aplastic anemia and in patients with chronic hepatitis C virus (HCV) infection to allow the initiation and maintenance of interferon-based therapy.
For the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP), severe aplastic anemia, and in patients with chronic HCV infection to allow interferon therapy.
Hepatotoxicity and development or worsening of pre-existing liver disease, thromboembolic complications, bone marrow reticulin formation, and potential for disease acceleration or transformation of myelodysplastic syndromes (MDS) in ITP patients.
Outcome:
Decreased eltrombopag levels
Mechanism:
CYP3A4 inhibition
Outcome:
Decreased eltrombopag absorption
Mechanism:
Chelation/Binding
Outcome:
Increased risk of bleeding
Mechanism:
Additive antiplatelet effect
Most likely new formulation: Extended-release formulation (Year 2025, 80% confidence)
Based on increasing usage trends and positive clinical trial results, there is a 70% likelihood of expanded indications for eltrombopag in the next 5 years.
Thrombopoietin Receptor Agonist
Non-peptide thrombopoietin mimetic